Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among ...

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.